ASCO GI 2022 Conference Coverage

 

ASCO GI 2022 Conference Coverage
F

ASCO GI 2022 Updates on Integrating New Targeted Therapy Into Locoregional Treatment of Localized ICC

By ASCO GI 2022 Conference Coverage FEATURING Flavio Rocha
By ASCO GI 2022 Conference Coverage FEATURING Flavio Rocha
0 views
January 26, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

15:07
Exelixis

Safety and Efficacy Data of a TKI Monotherapy in HCC

Feat. J. Mizrahi

Featured Video

20:00
Exelixis

Child-Pugh Classification and its Role in Treatment Decisions in Pat…

Feat. P. Gholam
Videos
12:45
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Biliary Cancer Updates

Feat. K. Spencer
09:37
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Updates in HCC

Feat. S. Sadeghi
05:42
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Pembro +/- Chemo vs. Chemo Alone for PD-L1+ Advanced GC…

Feat. Z. Wainberg
14:06
ASCO GI 2022 Conference Coverage

ASCO GI 2022 on the Emerging Roles of ctDNA as a Tool in Metastatic …

Feat. A. Dasari
08:15
ASCO GI 2022 Conference Coverage

ASCO GI 2022 on a Quality-Adjusted Time Without Symptoms or Toxicity…

Feat. R. Sugarman
11:37
ASCO GI 2022 Conference Coverage

ASCO GI 2022 CRC Cases: Is It Time to De-Intensify Oxaliplatin to Im…

Feat. G. A. Brooks
06:54
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Results From the PREVAIL ctDNA Study: Liquid Biopsy for…

Feat. J. Mencel
13:14
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Highlights on a Multicenter Phase II Study of Neoadjuva…

Feat. R. Kelly
13:50
ASCO Gastrointestinal Cancers Symposium

[PRIVATE - new ASCO version uploaded] ASCO GI 2022 Updates on the En…

Feat. V. Morris
20:21
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Review of the Emerging Roles of ctDNA as a Tool for Ear…

Feat. N. Starling
05:49
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Updates on the Dose-Escalation & Dose-Expansion Stu…

Feat. Y. Y. Janjigian
08:07
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Phase I/II Study of Regorafenib and Pembrolizumab in Re…

Feat. A. Barzi
12:23
ASCO GI 2022 Conference Coverage

ASCO GI 2022 on Chemo and CRT Neoadjuvant Regimens for Locally Advan…

Feat. K. Kato
22:39
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Updates on Integrating New Targeted Therapy Into Locore…

Feat. F. Rocha
05:54
ASCO GI 2022 Conference Coverage

ASCO GI 2022 on mFOLFOX6/Bev +/- Nivo for 1L Treatment of mCRC: Phas…

Feat. H. Lenz
14:00
ASCO GI 2022 Conference Coverage

ASCO GI 2022 on Triplet vs. Doublet Systemic Therapy for Advanced Re…

Feat. H. K. Sanoff
10:58
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Updates on FOLFOX + nab-Paclitaxel (FOLFOX-A) in the Tr…

Feat. A. Benson
05:04
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Updates on IO for Early Stage HCC

Feat. A. Villanueva
05:07
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Long-Term Follow-Up of the GERCOR NIPICOL Study: One-Ye…

Feat. R. Cohen
08:49
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Update on NIVO+ Chemo vs Chemo as 1L Treatment for Adva…

Feat. K. Shitara
07:30
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Updates on IMbrave150 Trial: Exploratory Efficacy &…

Feat. H. Chong Toh
04:05
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Highlights: Host-Related Biomarkers Including Gut Micro…

Feat. Y. Sunakawa
09:44
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Highlights: Clinical Utility of MSI-H Identified on Liq…

Feat. P. Kasi